Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion type Assertion NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_head.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion description "[Our results suggest that PSK may augment anti-tumour action via genes including multidrug resistance protein 3 (MRP3), lymphotactin (Lptn), transgelin (TAGLN), and Pirin, without disturbing cell-cycle progression, and may deserve a large clinical trial in cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion evidence source_evidence_literature NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion SIO_000772 15547752 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion wasDerivedFrom befree-20150227 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion wasGeneratedBy ECO_0000203 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.